1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Colon Cancer - Pipeline Review, H1 2020, provides an overview of the Colon Cancer (Oncology) pipeline landscape.
Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Colon Cancer - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Colon Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colon Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 22, 53, 8, 206, 30 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 4, 2, 43 and 13 molecules, respectively.
Colon Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Colon Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colon Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colon Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colon Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colon Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colon Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colon Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Colon Cancer - Overview
- Colon Cancer - Therapeutics Development
- Colon Cancer - Therapeutics Assessment
- Colon Cancer - Companies Involved in Therapeutics Development
- Colon Cancer - Drug Profiles
- Colon Cancer - Dormant Projects
- Colon Cancer - Discontinued Products
- Colon Cancer - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Colon Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Colon Cancer - Pipeline by 1ST Biotherapeutics Inc, H1 2020
- Colon Cancer - Pipeline by ABL Bio Inc, H1 2020
- Colon Cancer - Pipeline by ACF Pharmaceuticals LLC, H1 2020
- Colon Cancer - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
- Colon Cancer - Pipeline by Actym Therapeutics Inc, H1 2020
- Colon Cancer - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2020
- Colon Cancer - Pipeline by Aduro BioTech Inc, H1 2020
- Colon Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2020
- Colon Cancer - Pipeline by Adze Biotechnology Inc, H1 2020
- Colon Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2020
- Colon Cancer - Pipeline by Trillium Therapeutics Inc, H1 2020
- Colon Cancer - Pipeline by TVAX Biomedical Inc, H1 2020
- Colon Cancer - Pipeline by Tychon Bioscience Inc, H1 2020
- Colon Cancer - Pipeline by Tyg Oncology Ltd, H1 2020
- Colon Cancer - Pipeline by Tyme Technologies Inc, H1 2020
- Colon Cancer - Pipeline by Vault Pharma Inc, H1 2020
- Colon Cancer - Pipeline by Veana Therapeutics LLC, H1 2020
- Colon Cancer - Pipeline by Vernalis R&D Ltd, H1 2020
- Colon Cancer - Pipeline by Viomedix LLC, H1 2020
- Colon Cancer - Pipeline by Viracta Therapeutics Inc, H1 2020
- Colon Cancer - Pipeline by Virogin Biotech Ltd, H1 2020
- Colon Cancer - Pipeline by Well Marker Bio Co Ltd, H1 2020
- Colon Cancer - Pipeline by Wellmarker Bio Co Ltd, H1 2020
- Colon Cancer - Pipeline by Westwood Bioscience Inc, H1 2020
- Colon Cancer - Pipeline by WntResearch AB, H1 2020
- Colon Cancer - Pipeline by Wuhan Binhui Biotechnology Co Ltd, H1 2020
- Colon Cancer - Pipeline by Wuhan YZY Biopharma Co Ltd, H1 2020
- Colon Cancer - Pipeline by XOMA Corp, H1 2020
- Colon Cancer - Pipeline by Y-mAbs Therapeutics Inc, H1 2020
- Colon Cancer - Pipeline by Yuhan Corp, H1 2020
- Colon Cancer - Pipeline by Zenith Epigenetics Ltd, H1 2020
- Colon Cancer - Pipeline by Zovis Pharmaceuticals, H1 2020
- Colon Cancer - Dormant Projects, H1 2020
- Colon Cancer - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Colon Cancer, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 1ST Biotherapeutics Inc
- ABL Bio Inc
- ACF Pharmaceuticals LLC
- Actinium Pharmaceuticals Inc
- Actym Therapeutics Inc
- Adgero Biopharmaceuticals Holdings Inc
- Aduro BioTech Inc
- Advanced Cancer Therapeutics LLC
- Adze Biotechnology Inc
- Aeglea BioTherapeutics Inc
- Affimed GmbH
- Agenus Inc
- AGV Discovery SAS
- AIMM Therapeutics BV
- Alfasigma SpA
- Alligator Bioscience AB
- Alpine Immune Sciences Inc
- Amarin Corp Plc
- Ambrx Inc
- Amrita Therapeutics
- ANP Technologies Inc
- Aphios Corp
- Apollomics Inc
- AptaBio Therapeutics Inc
- Arbele Ltd
- Ariz Precision Medicine Inc
- Ascelia Pharma AB
- AskAt Inc
- aTyr Pharma Inc
- Aurigene Discovery Technologies Ltd
- Avican Inc
- Avidin Ltd
- Bayer AG
- Baylx Inc
- Beijing Fogangren Bio-Pharm Tech Co Ltd
- BeyondSpring Inc
- Binjiang Pharma, Inc.
- Biogazelle NV
- BioMed Valley Discoveries Inc
- Biomunex Pharmaceuticals
- Black Diamond Therapeutics Inc
- Bliss Biopharmaceutical (Hangzhou) Co Ltd
- Blueprint Medicines Corp
- Boehringer Ingelheim International GmbH
- Bold Therapeutics Inc
- Calidi Biotherapeutics Inc
- Can-Fite BioPharma Ltd
- Cancer Prevention Pharmaceuticals Inc
- Cancure Ltd
- Canget BioTekpharma LLC
- CARsgen Therapeutics Ltd
- Celldex Therapeutics Inc
- Cellective BioTherapy Inc
- Celprogen Inc
- CG Oncology Inc
- ChemoCentryx Inc
- Chipscreen Biosciences Ltd
- Clover Biopharmaceuticals
- CMG Pharmaceutical Co Ltd
- Codiak BioSciences Inc
- Convert Pharmaceuticals SA
- CStone Pharmaceuticals Co Ltd
- Cureport Inc
- CV6 Therapeutics (Ni) Ltd
- Cytocom Inc
- Cytodyn Inc
- CytomX Therapeutics Inc
- CZ BioMed Corp
- DEKK-TEC Inc
- Diazon Pharmaceuticals Inc
- DiNonA Inc
- Disulfican Ltd
- Diverse Biotech Inc
- Domainex Ltd
- Dracen Pharmaceuticals Inc
- Eli Lilly and Co
- Emcure Pharmaceuticals Ltd
- EncuraGen Inc
- Enochian Biosciences Inc
- EntreChem SL
- EnzymeBioSystems
- Epigene Therapeutics Inc
- Ervaxx Ltd
- Etubics Corp
- Evelo Biosciences Inc
- Evestra Inc
- Evotec SE
- F-star Biotechnology Ltd
- Felicitex Therapeutics Inc
- For-Robin Inc
- Fujifilm Holdings Corp
- Fusion Antibodies Plc
- G1 Therapeutics Inc
- GeoVax Labs Inc
- GlaxoSmithKline Plc
- GlycaNova AS
- GlycoMimetics Inc
- GlycoNex Inc
- GlyTR Therapeutics Inc
- GO Therapeutics Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Hamlet Pharma AB
- HengRui YuanZheng Bio-Technology Co Ltd
- Hibiskus Biopharma Inc
- HitGen LTD
- Horizon Therapeutics Plc
- Huabo Biopharm Co Ltd
- Hummingbird Bioscience Pte Ltd
- I-Mab Biopharma Co Ltd
- i2 Pharmaceuticals Inc
- Ikena Oncology Inc
- Ildong Pharmaceutical Co Ltd
- ImCheck Therapeutics SAS
- Immix BioPharma Inc
- Immune Modulation Inc
- Immunicum AB
- ImmunityBio Inc
- Immunos Therapeutics AG
- Immunotope Inc
- IMPACT Therapeutics Inc
- Infinity Pharmaceuticals Inc
- Inmune Bio Inc
- Innate Pharma SA
- Innopharmax Inc
- Intensity Therapeutics Inc
- InteRNA Technologies BV
- iOmx Therapeutics AG
- J-Pharma Co Ltd
- JenKem Technology Co Ltd
- Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
- Jiangsu Kanion Pharmaceutical Co Ltd
- JN Biosciences LLC
- JW Pharmaceutical Corp
- Kadmon Corp LLC
- KAHR medical Ltd
- Karyopharm Therapeutics Inc
- Kineta Inc
- Kitov Pharma Ltd
- Kolon Life Science Inc
- Kringle Pharma Inc
- Kymab Ltd
- LipoSeuticals Inc
- Lixte Biotechnology Holdings Inc
- MabVax Therapeutics Holdings Inc
- Machavert Pharmaceuticals LLC
- MacroGenics Inc
- Mateon Therapeutics Inc
- MaxiVAX SA
- Medicenna Therapeutics Corp
- Medicon Pharmaceuticals Inc
- Merck & Co Inc
- Merck KGaA
- MicroQuin Ltd
- Midissia Therapeutics Inc
- Millennium Pharmaceuticals Inc
- Multimmune GmbH
- MultiVir Inc
- Nanjing Jinsirui Biotechnology Co Ltd
- NED Biosystems Inc
- Northern Biologics Inc
- Northwest Biotherapeutics Inc
- Novartis AG
- Novita Pharmaceuticals Inc
- Novonco Pharmaceuticals Inc
- Obio Technology (Shanghai) Corp Ltd
- Oceanyx Pharmaceuticals Inc
- Omeros Corp
- Oncocross Co Ltd
- Oncorus Inc
- Oncovir Inc
- Oncoxx Biotech Srl
- Oneness Biotech Co Ltd
- Ono Pharmaceutical Co Ltd
- Orano Med LLC
- Orpheus Therapeutics Inc
- Pacylex Pharmaceuticals Inc
- Patrys Ltd
- Pfizer Inc
- PharmAbcine Inc
- PharmaCyte Biotech Inc
- Phenex Pharmaceuticals AG
- Photolitec LLC
- PHusis Therapeutics Inc
- Pionyr Immunotherapeutics Inc
- PNB Vesper Life Science Pvt Ltd
- Primetime Life Sciences LLC
- Protexase Therapeutics Inc
- Provecs Medical GmbH
- Provectus Biopharmaceuticals Inc
- PTC Therapeutics Inc
- Qilu Puget Sound Biotherapeutics Corp
- Qu Biologics Inc
- Resarci Therapeutics LLC
- Resonant Therapeutics Inc
- Rexahn Pharmaceuticals Inc
- Riptide Bioscience Inc
- Rubius Therapeutics Inc
- Sagimet Biosciences
- Sareum Holdings Plc
- Savoy Pharmaceuticals Inc
- Schrodinger LLC
- Scopus BioPharma Inc
- SEEKYO Therapeutics
- Senex Biotechnology
- SetLance srl
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Pharmaceutical Group Co Ltd
- Shaperon Inc
- Shattuck Labs Inc
- Shionogi & Co Ltd
- Shouyao Holding Co Ltd
- Sichuan Huiyang Life Science and Technology Corp
- SideROS
- SignPath Pharma Inc
- Silicon Therapeutics LLC
- Somantix BV
- Soricimed Biopharma Inc
- Sorrento Therapeutics Inc
- Sphaera Pharma Pte Ltd
- Spring Bank Pharmaceuticals Inc
- Stcube Inc
- Sun BioPharma Inc
- Suzhou Sinovent Pharmaceuticals Co Ltd
- Suzhou Stainwei Biotech Inc
- Tactical Therapeutics Inc
- Taiho Pharmaceutical Co Ltd
- Takis Srl
- Talapo Therapeutics Inc
- TargaGenix Inc
- Tarus Therapeutics Inc
- TenCure Ltd
- TeneoBio Inc
- TheraBioPhama
- Theralase Technologies Inc
- Theravectys SA
- Tianjin Hengjia Biotechnology Development Co Ltd
- Tiziana Life Sciences Plc
- Toray Industries Inc
- Transcenta Holding Ltd
- Transgene Biotek Ltd
- Transgene SA
- Trillium Therapeutics Inc
- TVAX Biomedical Inc
- Tychon Bioscience Inc
- Tyg Oncology Ltd
- Tyme Technologies Inc
- Vault Pharma Inc
- Veana Therapeutics LLC
- Vernalis R&D Ltd
- Viomedix LLC
- Viracta Therapeutics Inc
- Virogin Biotech Ltd
- Well Marker Bio Co Ltd
- Wellmarker Bio Co Ltd
- Westwood Bioscience Inc
- WntResearch AB
- Wuhan Binhui Biotechnology Co Ltd
- Wuhan YZY Biopharma Co Ltd
- XOMA Corp
- Y-mAbs Therapeutics Inc
- Yuhan Corp
- Zenith Epigenetics Ltd
- Zovis Pharmaceuticals
